JUJorge Hernando Ulloa

Jorge Hernando Ulloa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jorge Hernando Ulloa has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effectiveness of Conservative Treatment on Chronic Venous Disease Symptoms and Quality of Life in Patients with Type 2 Diabetes: Results from a Subanalysis of the VEIN STEP Observational Study

    by Jorge Hernando Ulloa, Zoubida Tazi Mezalek, Alejandro José González Ochoa, Faezeh Hosseini Sadrabadi, Vanessa Blanc-Guillemaud, Jean-Christophe Philips, Toni Feodor

    Background: This post-hoc subanalysis of the VEIN STEP study assessed the effectiveness of conservative treatment, particularly venoactive drugs (VAD), in reducing chronic venous disease (CVD) signs and symptoms and improving quality of life (QoL) for patients with type 2 diabetes (T2D) in a real-life setting. Methods: VEIN STEP was an observational, prospective study conducted in adult outpatients who consulted for symptomatic CVD (NCT04574375). CVD symptoms (10-cm Visual Analog Scale and Patient Global Impression of Change), disease severity (Venous Clinical Severity Score), and QoL (Chronic Venous Insufficiency Questionnaire [CIVIQ-14]) were assessed. Results: Overall, 6084 patients were analyzed, of whom 702 (11.5%) had T2D. These patients were more likely to be older, present with a more advanced CEAP class, have a higher body mass index, greater symptom severity and reduced QoL scores than those without T2D (p< 0.001 for all). Almost all patients with T2D (97.3%) received VAD-based treatment, mainly micronized purified flavonoid fraction (MPFF, 72.2%) or diosmin (24.6%). After 4 weeks, conservative therapy was associated with significant improvements in CVD symptoms and QoL (p< 0.001). Physicians also noted a significant improvement in disease severity (p< 0.001). The decrease in global symptom intensity was significantly greater among patients treated with MPFF than in those treated with diosmin (mean − 2.7± 1.8 vs − 2.0± 1.8, p=0.004). Greater reductions in symptom intensity were also observed in patients treated with MPFF for pain (p=0.011), leg heaviness (p=0.006), and swelling (p=0.014), with a tendency for greater improvement of cramps. QoL improved for patients receiving MPFF and those receiving diosmin, with changes in CIVIQ-14 global index score of − 21.3± 15.8 and − 15.5± 14.6, respectively. Conclusion: These findings indicate that patients with concomitant CVD and T2D are more likely to have greater symptom severity and disease burden. In such patients, VAD-based conservative therapy, particularly MPFF, was associated with significant improvements in CVD-related symptoms and QoL. Plain Language Summary: Chronic venous disease (CVD) is a common condition that often coexists with type 2 diabetes (T2D), with which it shares many risk factors such as aging, obesity, and inactive lifestyles. The VEIN STEP observational study included over 6,000 patients with CVD, 11.5% of whom also had T2D. Subjects with both conditions had worse symptoms, more severe disease, and lower quality of life than those with CVD alone. For the majority, interventions consisted of non-surgical treatments such as compression therapy and venoactive drugs, especially micronized purified flavonoid fraction (MPFF) and diosmin. There is a strong connection between CVD and T2D and the presence of one condition should prompt physicians to examine the patient for the other. This study shows that early diagnosis and treatment can significantly reduce CVD symptoms and improve quality of life. It also calls for more attention to managing CVD in people with T2D to reduce complications and improve outcomes.

  • Open Access

    Safety and Effectiveness of Negative Pressure Wound Therapy (Avelle) on Venous Leg Ulcers: The SPACE Study

    by Jorge Ulloa, Valentin Figueroa, Antonio Solano, Gwen Lawrence, Jorge H. Ulloa

    Introduction Hard-to-heal wounds represent a substantial burden on patients’ quality of life and healthcare systems. Negative pressure wound therapy (NPWT) is an advanced therapy used to manage hard-to-heal wounds as an adjunct to standard wound care; however, there are limited data on its clinical effectiveness. The aim of this study was to evaluate the clinical effectiveness and safety of the Avelle NPWT system in hard-to-heal venous leg ulcers (VLUs). Methods This was a single-arm, single-center, open-label, prospective study (NCT05666570) conducted in a Colombian outpatient setting. Patients with a venous ulcer, as per Clinical, Etiological, Anatomical, and Pathophysiological (CEAP) Classification C6/C6R, that has not progressed by >30% in the previous 4 weeks were enrolled. Eligible patients received NPWT at the screening/baseline visit (Visit 1) with scheduled follow-up visits on Day 6 ± 1 (Visit 2) and Day 13 ± 1 (Visit 3; end of study). The primary endpoints were baseline change in wound size and dressing durability. Secondary endpoints included clinical wound characteristics and device-related adverse events. Results Fifty-nine patients (median age: 66 years) with VLUs were enrolled (intention-to-treat population). In the per protocol population (n=50), the mean ± standard deviation wound area was 13.4 ± 17.0 cm2 at baseline and 7.3 ± 9.9 cm2 at study completion (46.8% reduction; p<0.001). Median dressing wear time was 6 days, and changes due to dressing saturation were reported in ≤ 3 (6%) patients. One VLU had completely healed. Erythema was the most common peri-wound skin condition at baseline (n=31, 62%) but decreased at the end of the study (n=26, 54%). Throughout the study, ≤ 6 (13%) patients had signs of eczema/dermatitis, hyperkeratotic callus, maceration, or edema, and there were no signs of infection. One patient experienced device-related dermal lesions resulting in study withdrawal, and one patient had a serious adverse event (not related to the device). Conclusions Management of hard-to-heal VLUs with NPWT for 2 weeks was associated with a significant reduction in wound size, as well as effective exudate control and a good safety profile. These results, combined with features of the device such as portability and ease of use, suggest it could be an effective treatment option in hard-to-heal wounds.


  • Open Access

    Correction to: VEIN STEP: A Prospective, Observational, International Study to Assess Effectiveness of Conservative Treatments in Chronic Venous Disease

    by Zoubida Tazi Mezalek, Toni Feodor, Larisa Chernukha, Zhong Chen, Ana Rueda, Ignacio Escotto Sánchez, Alejandro José González Ochoa, Joanna Chirol, Vanessa Blanc-Guillemaud, Caroline Lohier-Durel, et al.

    The online version of this article (10.1007/s12325-024-02857-2) contains supplementary material, which is available to authorized users.

  • Systematic literature review and expert meeting report on health-related quality of life in chronic venous disease

    by Jorge H. Ulloa, Fedor Lurie, Fabricio R. Santiago, Sergio Gianesini, Lourdes Reina, Jinsong Wang, Ravul Jindal, Wassila Taha, Mamuka Bokuchava, Armando Mansilha

    Article: Systematic literature review and expert meeting report on health-related quality of life in chronic venous disease - International Angiology 2023 Nov 28 - Minerva Medica - Journals


  • Open Access

    Correction to: VEIN STEP: A Prospective, Observational, International Study to Assess Effectiveness of Conservative Treatments in Chronic Venous Disease

    by Zoubida Tazi Mezalek, Toni Feodor, Larisa Chernukha, Zhong Chen, Ana Rueda, Ignacio Escotto Sánchez, Alejandro José González Ochoa, Joanna Chirol, Vanessa Blanc-Guillemaud, Caroline Lohier-Durel, et al.

  • Open Access

    VEIN STEP: A Prospective, Observational, International Study to Assess Effectiveness of Conservative Treatments in Chronic Venous Disease

    by Zoubida Tazi Mezalek, Toni Feodor, Larisa Chernukha, Zhong Chen, Ana Rueda, Ignacio Escotto Sánchez, Alejandro José González Ochoa, Joanna Chirol, Vanessa Blanc-Guillemaud, Caroline Lohier-Durel, et al.

    Introduction VEIN STEP was conducted to collect international data on the management of chronic venous disease (CVD) and to assess the effectiveness of conservative treatments for the relief of CVD signs and symptoms. Methods This international, observational, prospective, longitudinal, cohort study recruited adult outpatients consulting for symptomatic CVD. The primary objective was the effectiveness of conservative treatments on symptoms, signs and quality of life in a real-life setting assessed using a range of patient-reported outcome measures: 10-cm Visual Analog and Patient Global Impression of Change scales for symptoms; Venous Clinical Severity Score for physician assessment of signs; and 14-item ChronIc Venous Insufficiency Questionnaire (CIVIQ-14) for quality of life. At inclusion, patients were prescribed conservative treatment according to the physicians’ usual practice. Follow-up visits took place at weeks 2 and 4, with an optional week 8 visit. Results The analysis set comprised 6084 subjects (78% female) from nine countries with a mean age of 50.6 ± 13.8 years and BMI of 28.0 ± 4.9 kg/m2. The most common CEAP classifications were C1 (23.0%), C2 (31.6%), and C3 (30.7%). Conservative therapy consisted of oral venoactive drugs (VADs; 95.8% of subjects) including micronized purified flavonoid fraction (MPFF 75.5%) and diosmin (18.8%), compression (52.0%), and topicals (31.5%). Conservative therapy led to global symptom improvement in 89% of patients after 2 weeks and 96% at 4 weeks. Pain, leg heaviness, cramps, and sensation of swelling were improved in 82%, 71%, 45.5%, and 46% of patients, respectively. Conservative therapy was associated with a decrease over time in patient-assessed global symptom intensity: – 2.37 ± 1.73 (P < 0.001) and physician-assessed disease severity – 1.83 ± 2.82 (P < 0.001). Among the VADs, MPFF-based conservative therapy was associated with the greatest reduction in symptom and sign intensity. Improvements in CIVIQ-14 were observed with all treatments but were greatest for MPFF. Conclusion In this prospective study conducted in the real-world setting, treatment with conservative therapy, in particular MPFF, was associated with meaningful improvements in the clinical signs and symptoms of disease as well as in quality of life in patients with CVD. Trial Registration ClinicalTrials.gov identifier NCT04574375.


  • Open Access

    Optimising Decision Making in Chronic Venous Disease Management with Micronised Purified Flavonoid Fraction

    by Jorge H. Ulloa

    Evidence-based medicine favours randomised controlled trials to limit bias and establish the effects of a treatment with statistical rigour. However, the controlled conditions and careful patient selection of randomised trials may produce results that cannot be generalised to a more diverse patient population in clinical practice. Therefore, there is growing recognition of the importance of supplementing randomised trial data with real-world evidence. Micronised purified flavonoid fraction has been investigated in several large-scale real-world studies, including the RELIEF and DECIDE studies, each of which included more than 1000 patients with chronic venous disease. These studies demonstrated a significant reduction in the prevalence and severity of chronic venous disease symptoms, and an improvement in quality of life. The chronic VEnous dIsorders maNagement and treatment effectivenesS evaluaTion in chronic vEnous disease, an international Program (VEINSTEP) study (NCT04574375), is currently underway in more than 6000 patients with chronic venous disease in nine countries. Preliminary data from one country (Morocco) indicate that chronic venous disease drug treatment, which was micronised purified flavonoid fraction in 75.7% of patients, was associated with a statistically significantly reduction in symptoms and improved quality of life. The overall results are awaited with interest. International chronic venous disease guidelines grade the evidence for micronised purified flavonoid fraction highly, as the benefits of micronised purified flavonoid fraction have been proven in randomised clinical trials and meta-analyses. Real-world studies demonstrate that the randomised evidence for micronised purified flavonoid fraction is generalisable to a clinical practice setting. Treatment decisions in chronic venous disease should consider evidence-based recommendations, including real-world data, as well as patient goals of symptom relief, functional improvement and/or better quality of life.


  • Proper technique of lower extremity pulse examination: a lost art

    by Keith D. Calligaro, Frank J. Veith, George Berdejo, Jorge H. Ulloa

    Article: Proper technique of lower extremity pulse examination: a lost art - International Angiology 2023 Jan 12 - Minerva Medica - Journals


  • Comment on "Endovenous microwave ablation of varicose veins: early Egyptian experience"

    by Jorge H. Ulloa, Sebastian Cifuentes, Antonio Solano

    Article: Comment on “Endovenous microwave ablation of varicose veins: early Egyptian experience” - Acta Phlebologica 2022 December;23(3):131-2 - Minerva Medica - Journals

  • Curación de úlceras venosas crónicas inducida con un hidrogel de aloe vera, sorbitol, alantoína y glicerol

    by Jorge H. Ulloa, Javier Bravo, Oscar Y. Moreno, Sebastián Cifuentes, José Ordoñez, Valentín Figueroa